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Chapter 10
Summary, conclusions and perspectives
Summary
Multidrug resistance is one, well-defined, way in which tumors become resistant o che-
motherapeutic drugs. The main characteristic of multidrug resistant umor cells is the phe-
nomenon of cross-resistance of these cells against a panel of, in general natural, structural
non-related chemotherapeutic drugs, such as anthracyclines, vinca-alkaloids, and epipo-
dophyllotoxins. In the classic form multidrug resistant umor cells overexpress a 170 kDa
membrane protein, called P-glycoprotein, which acts as a membrane efflux pump, thus
leading to decreased cellular levels of chemotherapeutic drugs, which account for a de-
crease in cytotoxicity. Recently, an other form of multidrug resistance has been defined,
the so-called non-P-glycoprotein multidrug resistance. In non-P-glycoprotein multidrug
resistant tumor cells either efflux pumps different from P-glycoprotein can be demonst-
rated, or overexpression of mRNA encoding for MRP, a multidrug resislant associated
protein, can be detected. This MRP is a member of a family of energy-dependent mem-
brane drug transporters to which also belongs P-glycoprotein, the product of the human
MDRI gene. In the atypical form of multidrug resistance tumor cells are phenotypically
multidrug resistant, but overexpression of P-glycoprotein can not be detected. Instead an
alteration or decrease is found in topoisomerase II activity. This toposiomerase II is an
enzyme involved in DNA replication, and a target of various anticancer drugs, including
the anthracyclines and epipodophyllotoxins.
In daily practice multidrug resistance is a problem with which every clinical oncolo-
gist has to deal. Many patients with metastatic disease have tumors which are already
resistant at presentation or become resistant during the clinical follow-up. This thesis
comprises various in vitro and in vivo studies in which ways to circumvent multidrug
resistance are described.
In chapter I a review is given about the phenomenon of multidrug resistance and current
approaches to circumvent it. Many successful modulators of multidrug resistance were
detected in the laboratory. Since 1987 results of clinical studies, combining chemothera-
peutic drugs with resistance modifiers, have been published. The results of such studies
in solid tumors are in general disappointing. The best option for this concept seems to be
some hematologic malignancies, as efficacy has especially been observed in malignant
lymphoma and multiple myeloma.
Chapter 2 comprises results of our investigations with amiodarone, like verapamil a well-
known modulator of multidrue resistance. In the laboratorv amiodarone showed to be a
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strong potentiator of cytotoxicity induced by doxorubicin, vincristine and etoposide in
COLO 320, a human colon carcinoma cell line which overexpresses P-glycoprotein. In
contrast, in the P-glycoprotein negative sensitive parental human small cell lung cancer
cell line GLC4 and in its doxorubicin resistant cell line GLC4-Adr, which is also P-glyco-
protein negative, but has an increased MRP expression ancl a lowered topoisornerase II
activity compared to GLC4, amiodarone did not increase the doxorubicin cytotoxicity.
Arniodarone was an inhibitor of doxorubicin efflux in COLO 320 cells, whereas doxo-
rubicin diminished amiodarone efflux from these cells, suggesting competition for one
efflux pump. In COLO 320 more intracellular, and especially intranuclear, doxorubicin
fluorescence and more doxorubicin-induced double stranded DNA damage were found
after co-exposure to amiodarone, and amiodarone also increased the amount of etoposide-
induced topoisomerase II-DNA complexes in these cells. ln normal bone marrow amio-
darone did not enhance doxorubicin damage. In a phase 2 study 14 patients with intrinsic
or acquired doxorubicin resistance were treated with the combination of doxorubicin and
intravenous amiodarone. For this treatment patients were admitted on an intensive care
unit during one day. Neither serious toxicity due to intravenous amiodarone, nor an in-
crease in doxorubin induced toxicity were observed. Peak serum levels of amiodarone
plus its active metabolite were about 10 trtM, which comesponded with an in vitro effective
modulation concentration. One of 13 evaluable patients obtained a partial remission from
lung metastases of a soft tissue sarcoma.
In chapter 3 results of a second clinical study with amiodarone in patients with metastatic
presumedly intrinsic or acquired anthracycline resistant solid tumors are described. ln this
study amiodarone is given orally in high dosages one week prior to chemotherapy with
doxorubicin and vindesine. Twenty-five patients were included. The whole treatment
could be given in the out-patient department. One patient developed symptomatic cardiac
conduction delay, which necessitated withdrawal of amiodarone during the next chemo-
therapeutic course. Other toxicity was as might be expected from treatment with doxo-
rubicin and vindesine alone. Peak serum levels of amiodarone, taken just befbre the che-
motherapeutic infusion, were'7.J ;rM which is in vitro a still effective modulation concen-
tration. One of 24 evaluable patients had a partial response, with near complete disappear-
ance of lung metastases, of a P-glycoprotein positive leiomyosarcoma of the uterus.
Chapter 4 presents in vitro studies in which the efficacy of 59788, a new synthesized
modulator of multidrug resistance, was tesled and compared with the action of verapamil.
Maximal non-cytotoxic concentrations of 59788, a triazineaminopiperidine derivative,
and verapamil were tested in combination with doxorubicin, vinblastine or vincristine and
cytotoxicity was evaluated using either the clonogenic assay, the metabolic dye reduction
MTT assay, or monitoring growth inhibition. The potency of 59788 and verapamil to
modulate drug resistance in the various tumor cell lines tested was comparable. The high-
est dose modification factors were found in the 200-fold vinblastine resistant classic mul-
tidrug resistant subline CEM/VLB100. Both modulators were able to modify resistance
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in four intrinsic as well as four acquired drug resistant umor cell lines, all of which were
P-glycoprotein positive. However, in two P-glycoprotein negative drug resistant tumor
sublines with altered topoisomerase II activity (GLC4/ADR and CEMffM-l), no
resistance modulation by verapamil and 59788 was observed. 59788 was able to induce
more intracellular, and especially nuclear, doxorubicin fluorescence in P-glycoprotein
positive ovary tumor cells (2780AD).
In chapter 5 a review is given about mitoxantrone, an active anticancer drug and clinically
predominantly used in patients with breast cancer and acute leukemias. The in vitro work-
ing mechanisms and ways of resistance are discussed. In vivo toxicity, modes of adminis-
tration. and activity in various tumor types are described. As part of this thesis the incom-
plete cross-resistance with doxorubicin, in vitro as well as ir.r vivo, is of major interest.
Hence, this might be a way to treat patients with doxorubicin resistant umors.
ln chapters 6 and 7 the role of well-known multidrug resistance modulators in combination
with mitoxantrone, doxorubicin, and vincristine in various tumor cell lines is described.
In chapter 6 the effects of amiodarone, cyclosporin A and the cyclosporin A analogue
PSC 833, a recently synthesized modulator of P-glycoprotein mediated multidrug resist-
ance, are tested in the MTT assay in three human P-glycoprotein negative small cell lung
cancer cell lines (GLC4, GLC4-Adr, and the cisplatin resistant GLC4-CDDP). Of these
three cell lines CLC4-Adr is the only one with the multidrug resistant phenotype, as des-
cribed previously. In these cell lines amiodarone had no effect on the doxorubicin cyto-
toxicity, but it increased vincristine cytotoxicity and strongly potentiated mitoxantrone
cytotoxicity. Cyclosporin A did also not aff'ect cytotoxicity of doxorubicin, and only
potentiated vincristine cytotoxicity in GLC4 modestly when used in a high concentration.
In GLC4 and GLC4-CDDP. rnitoxantrone cytotoxicity was decreased in the presence of
cyclosporin A, whereas no effect was obser-ved in GLC4-Adr. PSC 833 did not affect
doxorubicin- or mitoxantrone cytotoxicity in these lines, but potentiated cytotoxicity of
vincristine in GLC4-Adr at the highest tested concentration of PSC 833. ln the clonogenic
assay the effects of amiodarone and cyclosporin A on mitoxantrone cytotoxicity in GLC4
in the MTT assay, were confinned. In normal bone man'ow amiodarone did not increase
mitoxantrone-induced toxicity. ln GLC4 amiodarolle co-exposure resulted in more mito-
xantrone-induced topoisomerase II-DNA complexes while cyclosporin A did not affect
the amount of these mitoxantrone-induced so-called cleavable complexes. Flow cytome-
try of cellular mitoxantrone fluorescence showed an increase in cellular mitoxantrone
after incubation of mitoxantrone with amiodarone. and an inhibition of eftlux in GLC4.
and GLC4-Adr, whereas cyclosporin A and PSC 833 did not affect mitoxantrone efflux.
Chapter 7 reports the role of amiodarone, cyclosporin A and PSC 833 on the cytotoxicity
of doxorubicin, mitoxantrone and vincristine in a P-glycoprotein positive tumor cell line,
COLO 320. Amiodarone, cyclosporin A, and PSC 833 proved to be potent modulators of
doxorubicin and vincristine resistance in this cell line. PSC 833 was l0-fold more active
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than cyclosporin A, which in turn was lO-fold more active as resistance modifier than
amiodarone. Amiodarone was a very effective potentiator of mitoxantrone cytotoxicity.
PSC 833 also increased mitoxantrone cytotoxicity, but to a lesser degree than amiodarone.
In contrast, cyclosporin A reduced mitoxantrone cytotoxicity. Cellular fluorescence of
mitoxantrone increased after co-exposure to either amiodarone, cyclosporin A or PSC
833. A change in efflux of mitoxantrone by one of these modulators was not observed.
Chapter 8 presents an analysis of the cytostatic actions of two members of the family of
morpholino anthracyclines, a new class of anthracycline derivatives, synthesized to be
less toxic, more potent, and non cross-resistant with doxorubicin. Methoxymorpholino-
and cyanomorpholino anthracycline were tested in the sensitive GLC4, the cisplatin
resistant GLC4-CDDP, the P-glycoprotein negative doxorubicin resistant GLC4-Adr, and
the P-glycoprotein positive COLO 320 cell lines. Both morpholino anthracyclines
showed hardly any cross-resistance for doxorubicin, the best known representative of the
anthracyclines. in both doxorubicin resistant cell lines. In contrast, in GLC4-CDDP the
cytotoxicity of the morpholino anthracyclines was less than in the sensitive GLC4. The
cyanomorpholinyl derivative was in all testecl cell lines about 2.5-fold more active than
the methoxymorpholino anthracycline. The cytotoxicity profile of the morpholino anthra-
cyclines was comparable with the cytotoxicity profile of camptothecin, suggesting
topoisomerase I as intracellular target for the morpholino anthracyclines.
ln conclusion, these new morpholinyl derivates of the anthracyciines eem not to be
influenced in their action by mechanisms of drug resistance as P-glycoprotein- , or non P-
glycoprotein mediated multidrug resistance. or altered topoisomerase II activity. Results
of clinical studies are expected with great interest to define the role of these new antican-
cer drugs in patients with resistant umors.
Chapter 9 describes in vitro and clinical studies with one member of the group of aryl-
methylaminopropanediols, BW502U83. This new chemotherapeutic drug showed partial
cross-resistance in the P-glycoprotein positive doxorubicin resistant COLO 320 cell line,
and in the P-glycoprotein negative doxorubicin resistant cell line GLC4-Adr. In the cis-
platin resistant GLC4-CDDP no cross-resistance was found. The working mechanism of
BW502U83 was studied extensively. Double stranded DNA damage could easily be
demonstrated. but did not correlate with the cytotoxicity of 8W502U83 in the tested cell
lines. BW502U83 did not form interstrand cross-links; intercalation was extensive.
Neither topoisomerase I, nor topoisomerase II interaction could be demonstrated.
Amiodarone had no effect on the cytotoxicity of BW502U83, suggesting an absence of P-
glycoprotein interaction of the drug.
Because of rapid metabolization and inactivation in the liver of BW502U83 when
administered intravenously to patients, a feasibility study was performed in which three
patients were treated intra-arterially. Two patients with surgical incurable liver cell cancer
were treated with BW502U83 in the hepatic artery. The first patient had a partial response
after the first of two courses. He also developed signs of a tumor lysis syndrome after the
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first course with transient renal failure. The second patient with liver cell cancer received
a total of four courses, which resulted in remarkable clinical improvemerrt. Radiographi-
cally however he had stable disease. A third patient with a soft tissue sarcoma, localized
in the pelvic region. had clinically and radiographically stable disease after two courses.
Systemic side effects were not observed.
Intra-arterial administration of BW502U83 seems a promising rnode of administration
of this non-multidrug resistance associated new anticancer drug.
Conclusions from this thesis
In this thesis amiodarone has been described as a potent modulator of P-glycoprotein
mediated doxorubicin- and vincristine resistance, but also as an agent able to enhance
mitoxantrone cytotoxicity in P-glycoprotein and non-P-glycoprotein MDR tumor cell
lines, and in sensitive and cisplatin resistant cell lines. In clinical studies, in which amio-
darone was added to MDR chemotherapeutic drugs, amiodarone achieved serum levels
corresponding with efiective MDR modulation concentrations in vitro. However, tumor
remissions were scarce. Toxicity of the chemotherapeutic drugs was not enhanced, and
amiodarone itself did not cause serious toxicity, thus making furlher studies with this
modulator leasib,'c.
In vifro 59788, a new synthesized triazineaminopiperidine derivative, proved its effi-
cacy in modulation in P-glycoprotein positive cell lines, but not in non-p-glycoprotein
MDR tumor cell lines. In our studies 59788 proved to be as effective as verapamil.
Cyclosporin A was lO-fold more potent in circumvention of doxorubicin- and vincris-
tine resistance in P-glycoprotein positive tumor cells than amiodarone, but protected from
mitoxantrone cytotoxicity in sensitive-, P-glycoprotein positive-, and cisplatin resistant
cells.
PSC 833, a new synthesized cyclosporin analogue, circumvented cloxorubicin- and
vincristine resistance in P-glycoprotein positive tumor cells, and potentiated mitoxantrone
cytotoxicity in P-glycoprotein positive tumor cells. As MDR resisrance modifier pSC 833
was 100-fold more active than amiodarone.
The morpholino anthracyclines, methoxymorpholino- and cyanomorpholino anthra-
cycline. were very porent chemotherapeutic drugs in both p-gtycoprotein and non-p-gly-
coprotein MDR tumor cells. It is possible that topoisomerase I is their intlacellular target.
These new anthracycline derivatives seem very promising drugs for the next oncologic
future.
The arylmethylaminopropanediol BW502U83 showed to be a partial cross-resisrant
intercalating chemotherapeutic drug in P-glycoprotein positive and negative cell MDR
lines and an active non-cross-resistant anticancer drug in a cisplatin resistant cell line. In
a clinical study intrar-arterial administration of this drug gave promising resulrs. Unfortu-
nately the toxicity of intravenous administration of the drug urged the pharmaceutical
company to withdraw this drug from further clinical trials.
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General conclusions and perspectives
After the first publications of Ling, concerning drug resistance and P-glycoprotein, much
more knowledge has been gathered about the structure and function of P-glycoprotein and
the multidrug resistant phenotype. Genes responsible for multidrug resistance have been
characterized and several proteins involved in MDR tumor cells have been demonsfrated.
Functional assays have been performed to show pump functions ofthese proteins or chan-
ges in intracellular distribution of chemotherapeutic drugs in MDR tumor cells.
Resistance modifying agents for P-glycoprotein mediated MDR have been detected
and are currently used in clinical studies. However many questions concerning MDR
remain.
The role of P-glycoprotein in normal tissues is still not fully elucidated. although there
are indications ofits activity in active transport ofendo- and exotoxins, steroid hormones,
and possibly also passive transport of chloride.
The development of new specitic P-glycoprotein resistance modifiers, such as PSC
833 and 59788, seems to be successful in vitro. However, their potential in clinical stud-
ies, especially in the treatment of resistant solid tumors, and their supposed lack of side-
effects remain to be proven.
A proper approach for clinical studies with resistance modifying agents, especially in
the treatment of solid tumors, has still to be fbund. When should a tumor be designated P-
glycoprotein positive, as neither the detection of P-glycoprotein or MDRl mRNA or the
MDR1 gene is proof of its functionality in the specific tumor, nor is the clinical relevant
detection limit of these assays known. How can it be proven that a certain resistance modi-
fier has reached the tumor, and that an in vivo effective concentration is achieved in the
tumor ? Serum levels of these modulators are often taken as representative for their action
at the tumor site, but presumably in solid tumors this is probably not a very reliable para-
meter. Therefore, functional detection methods are necessary to localize MDR related
pumps and show in vivo action of modulators. The recent report about the gamma-
emitting organotechnetium complex 99m1"-5B514MIBI, a lipophilic cationic radiophar-
maceutical which is able to image P-glycoprotein expression functionally by gamma
camera scintigraphy, might become one of these useful functional assays (1). Positron
emission tomography (PET), using either labelled chemotherapeutic drugs or labelled
resistance modifiers, might be another example of a functional assay for MDR in the near
future.
In general MDR positivity correlates with aggressiveness of the tumors and poor prog-
nosis of the patients (2-4). P-glycoprotein may influence behaviour of tumor cells in such
a way that they have an increased potential for dissemination. Clinical studies are ongoing
in which P-glycoprotein positive tumors are treated up-front, directly after diagnosis, with
MDR resistance modifiers combined with chemotherapy, in order to prevent massive
overgrowth of P-glycoprotein positive tumor cells in always heterogeneous tumors.
Biedler recently demonstrated in P-glycoprotein positive tumor cells that exposure to
verapamil resulted in modulation of amplified genes encoding P-glycoprotein (5). The
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decrease in P-glycoprotein expression was mainly due to gene deletion. This would be an
argument to treat patients with P-giycoprotein positive tumors at first wifh a resistance
modifier alone, in order to change the genotype of the tumor leading to knock-out of the
MDRI gene. However, the report of Herzog et al. about up-regulation of MDR1 mRNA
and P-glycoprotein after exposure of tumor cells to verapamil, cyclosporin A, and nifedi-
pine, just wams us for the adverse effects of treatment with MDR modulators alone (6).
Studies in MDR tumor cell lines show that P-glycoprotein is not the only cause of
resistance, and that different causes may occur together. Therefore, also solutions for the
problem of non-P-glycoprotein pumps, altered topoisomerase II activity, and enhanced
detoxification systems should be found. The protein kinase inhibitor genistein has demon-
strated its efficacy in restoration of a daunorubicin accumulation deficit and in increasing
the ratio of nuclear to cytoplasmic doxorubicin fluorescence in non-P-glycoprotein MDR
tumor cells (7). As might be expected more resistance moditiers of non-P-glycoprotein
mediated MDR will be synthesized. In vitro fostriecin has shown its activity in cells with
decreased topoisomerase II activity, and the first clinical studies with this new anticancer
drug started recently (8). Results of the first phase I studies with modulators of enhanced
detoxification systems, such as with the costly buthionine sulfoximine to circumvent
enhanced glutathione (GSH), and the diuretic ethacrynic acid to circumvent increased
gluathione S-transferase (GST) activity have been published recently (9,10). Phase 2
studies are ongoing.
A quite opposite approach in the MDR field is to make use of the presence or the intro-
duction of MDR in normal tissue. However, whether gerre manipulation with MDRI gene
transfection experiments in normal bone marrow in order to give ultra-high dosages of
chemotherapy in patients will add much to the present results of studies with intensive
chemotherapy followed by autologous bone marrow transplantation and stem cell re-
infusion seems doubtful (11,12). Hence, extra-medullary and not bone-manow toxicity is
the dose-limiting factor in these treatments.
In summary, despite all knowledge conceming MDR, positive results of clinical studies
in which different approaches to circumvent this devastating form of drug resistance have
been tested. are still scarce. To solve this problem intensive co-operation between workers
in the laboratory and the clinical field remains indispensable.
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